- Country: USA
- Summary: Notice of Intent to Sole Source Vitrolife
- UST Ref No: 121858862
- Deadline: 15 Jul 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: HT942525Q0630
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
The Defense Health Agency (DHA) U.S. Army Medical Research Acquisition Activity (USAMRAA) intends to award a Firm Fixed Price sole source contract on behalf of the Naval Medical Center San Diego (NMSCD) to Vitrolife, Inc., under the authority FAR 13.106-1(b)(1): For purchases not exceeding the simplified acquisition threshold (SAT), only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name, or industrial mobilization).
This requirement is for a Viscosity Treatment System, Enhance-S Plus Set, Sperm Wash Medium and the 20 um, 2-chamber MicroCell for fertility testing. These reagents and supplies required provide pre-chemotherapy screening and comprehensive infertility investigation for NMCSD patients.
Vitrolife, Inc. is the only vendor able to provide the reagents and supplies that can meet the current needs of NMCSD. Use of Vitrolife Inc. reagents and supplies will ensure the continuity of testing for the investigation of current conditions and or functions of existing systems. Any change to the product necessitates thorough investigation, assessment and approval of individual components utilized in the testing procedure in accordance with the Clinical and Laboratory Standards Institute (CLSI) and College of American Pathologist (CAP) accreditation requirements. Current Vitrolife system components in use are FDA approved, have been assessed, validated and approved for use, hence ready for use and require no further assessment for continued use beyond applicable accreditation requirements. Other reagents are available, however the methodology, kit/reagent complexity and/or protocols will require reassessment and revalidation if introduced. Modification of procedures will result in delays and/or necessity to refer patients to outside networks for service.
This is a notice of intent to issue a contract on a Sole Source basis. This notice of intent is NOT a request for quotations (RFQ). Any ... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINNotice of Intent to Sole Source Vitrolife - USA Tender
The DEPT OF DEFENSE | DEFENSE HEALTH AGENCY (DHA), a Government sector organization in USA, has announced a new tender for Notice of Intent to Sole Source Vitrolife. This tender is published on USARFP under UST Ref No: 121858862 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-07-15.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
